ME Therapeutics Holdings Inc. (CSE:METX)

Canada flag Canada · Delayed Price · Currency is CAD
2.500
0.00 (0.00%)
At close: Feb 24, 2026
-68.75%
Market Cap 75.12M
Revenue (ttm) n/a
Net Income (ttm) -1.25M
Shares Out 30.05M
EPS (ttm) -0.04
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 800
Average Volume 655
Open 3.700
Previous Close n/a
Day's Range 2.500 - 3.700
52-Week Range 2.000 - 11.000
Beta -0.17
RSI 42.93
Earnings Date Nov 27, 2025

About ME Therapeutics Holdings

ME Therapeutics Holdings Inc., a preclinical stage biotechnology company, engages in the development of cancer fighting drugs in the field of immuno‐oncology. The company’s lead candidate, h1B11-12, is a glycoprotein cytokine antibody drug that targets a key protein involved in the generation of suppressive myeloid cells for the treatment of colorectal cancer. It also develops D094 and D099, which are small molecule myeloid targeted prodrug candidates to treat cancer; and myeloid targeting lipid nanoparticles (LNPS) formulations. ME Therapeutic... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Country Canada
Stock Exchange Canadian Securities Exchange
Ticker Symbol METX
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.